Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 13/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471252 | 0.84 | PTGER2 (0.42) | PTGER2 | |
| SCHEMBL12749312 | 0.84 | PTGER2 (0.58) | PTGER2PTPN1 | |
| SCHEMBL1471083 | 0.81 | ALDH1A1 (0.42) | — | |
| SCHEMBL12981326 | 0.75 | PTGER2 (0.75) | PTGER2 | |
| SCHEMBL11634335 | 0.74 | LTB4R2 (0.47) | LTB4R2 | |
| SCHEMBL12981623 | 0.73 | PTGER2 (0.72) | PTGER2 | |
| SCHEMBL27664515 | 0.72 | PTGER2 (0.47) | PTGER2 | |
| SCHEMBL13572228 | 0.72 | PTGER2 (0.51) | PTGER2 | |
| SCHEMBL13399365 | 0.72 | CA12 (0.59) | PTGER2 | |
| SCHEMBL5050455 | 0.71 | CA12 (0.58) | PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142471-A1 | SULFONAMIDES | ALLERGAN, INC. | 2007-06-21 | — | — | US | claimed |
| US-7915316-B2 | Sulfonamides | ALLERGAN, INC (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1917238-A2 | SULFONAMIDES | Allergan, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070142471-A1 | SULFONAMIDES | ALLERGAN, INC. | 2007-06-21 | — | — | US | disclosed |
| WO-2007024860-A2 | SULFONAMIDES | ALLERGAN, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142471-A1 | SULFONAMIDES | CRYZ, QDPR, GLRX3 | PTGER2 1557/4885PTPN1 3220/4885LTB4R2 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.